DJ Blom
5 Papers
1 Citations
DJ Blom is an academic researcher. The author has contributed to research in topics: Internal medicine & Familial hypercholesterolemia. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
•Journal Article
Clinical approach to DYSLIPIDAEMIA
TL;DR: The critical importance of cholesterol is underscored by the large number of genes that regulate its metabolism and the devastating clinical consequences of the (luckily) very rare disorders in which ‘abnormal’ sterol molecules accumulate or cholesterol synthesis is disrupted.
4
Diagnosis, treatment and cardiovascular outcomes in homozygous familial hypercholesterolaemia: A sex-specific analysis
Janneke W.C.M. Mulder,T. R. Tromp,Mutaz Alkhnifsawi,S. Bertolini,DJ Blom,Krzysztof Chlebus,Marina Cuchel,Antonio Gallo,Gerard K Hovingh,Ngoc Thanh Kim,J. Long,Fj Raal,Thanh-Huong Truong,Eric Boersma,Jeanine E. Roeters van Lennep +14 more
TL;DR: This study compares cardiovascular outcomes in 751 patients with homozygous familial hypercholesterolaemia, finding no sex differences in age at diagnosis, treatment, or atherosclerotic cardiovascular disease outcomes, despite higher rates of myocardial infarction in men.
1
HoFH is a life limiting condition: Clinical characteristics and lifespan of deceased HoFH patients in the HICC registry
Janneke W.C.M. Mulder,T. R. Tromp,D. Reijman,Khalid Al-Waili,Mahmoud H. Ayesh,S. Bertolini,Vladimír Bláha,DJ Blom,Joel M. Brothers,Marina Cuchel,G. Francis,J. Genest,Mariko Harada-Shiba,Gerard K Hovingh,Fj Raal,R. Santos,Handrean Soran,Thanh-Huong Truong,I. Verma,L. Wang,Albert Wiegman,J. R. Van Lennep +21 more
TL;DR: This study of 37 deceased HoFH patients in the HICC registry reveals a life-limiting condition, with 76% dying from cardiovascular causes at a median age of 32 years, often with recurrent ASCVD and severe hypercholesterolemia.
1
Lomitapide in paediatric homozygous familial hypercholesterolemia – Real-world clinical experience from South Africa
TL;DR: Lomitapide is a microsomal transfer protein inhibitor that has demonstrated LDL receptor-independent lipid-lowering efficacy in homozygous familial hypercholesterolemia (HoFH) patients in long-term clinical trials and real-world studies as mentioned in this paper .
Treatment gaps in paediatric patients with homozygous familial hypercholesterolaemia
M. D. Reijman,T. R. Tromp,D. Meeike Kusters,Albert Wiegman,Johan W. Groothoff,DJ Blom,Frederick J. Raal,Marina Cuchel,Gerard K Hovingh +8 more
TL;DR: In this article , the authors compared use of LLT in children, adolescents and adults with homozygous familial hypercholesterolaemia (HoFH) from diagnosis to avoid premature atherosclerotic cardiovascular disease (ASCVD).